Edgewise Therapeutics CSO Alan Russell sells $258k in stock
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $EWTX +2.97% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$EWTX last traded at $38.80, +2.97% on the session. That puts it 20% shy of its 52-week high of $48.51 and 132% clear of its low of $16.70 — a little above the middle of the range. Over the year it has ranged 190% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $EWTX page.
How much coverage it is getting
Nothing else on $EWTX in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$EWTX earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $EWTX page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. And Wook AI, up top, will happily do the math — how far $EWTX sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $EWTX. It carried $258K, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 15, 2026. $EWTX has moved -11.90% ($44.04 to $38.80). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.